COVID-19 Vaccines: Current Status and Implication for Use in Indonesia

Area of Science:

• Vaccinology
• Infectious Diseases
• Public Health

Background:

• COVID-19 has caused global health and economic disruption, with Indonesia facing high case and fatality rates.
• Vaccine development for SARS-CoV-2 is progressing rapidly, offering a critical solution.

Purpose of the Study:

• To review various COVID-19 vaccine modalities, including mRNA, inactivated virus, viral vector, and protein subunit.
• To analyze safety, immunogenicity, and Phase II/III trial results of nine vaccine candidates.
• To discuss implications for vaccine use and distribution in Indonesia.

Main Methods:

• Literature review of COVID-19 vaccine development and clinical trial data.
• Analysis of vaccine platforms: mRNA, inactivated virus, viral vector, and protein subunit.
• Assessment of safety, immunogenicity, and efficacy data up to December 29, 2020.

Main Results:

• Several vaccine candidates utilizing diverse platforms are nearing Phase III completion.
• The BioNTech/Pfizer mRNA vaccine was the first licensed COVID-19 vaccine.
• Data on safety and immunogenicity across different vaccine types are being evaluated.

Conclusions:

• Multiple COVID-19 vaccine technologies show promise in combating the pandemic.
• Understanding vaccine characteristics is crucial for effective public health strategies in Indonesia.
• Rapidly evolving vaccine landscape necessitates ongoing review and updates.